tetano
Editor, Senior Moderator
Front Immunol
. 2020 Aug 18;11:2056.
doi: 10.3389/fimmu.2020.02056. eCollection 2020.
Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury
Xianyang Chen[SUP] 1 [/SUP], Huifang Guo[SUP] 1 [/SUP], Li Qiu[SUP] 2 [/SUP], Chengdong Zhang[SUP] 1 [/SUP], Qiang Deng[SUP] 3 [/SUP], Qibin Leng[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease 2019 (COVID-19), a disease which causes severe lung injury and multiple organ damage, presents an urgent need for new drugs. The case severity and fatality of COVID-19 are associated with excessive inflammation, namely, a cytokine storm. Metformin, a widely used drug to treat type 2 diabetes (T2D) mellitus and metabolic syndrome, has immunomodulatory activity that reduces the production of proinflammatory cytokines using macrophages and causes the formation of neutrophil extracellular traps (NETs). Metformin also inhibits the cytokine production of pathogenic Th1 and Th17 cells. Importantly, treatment with metformin alleviates various lung injuries in preclinical animal models. In addition, a recent proteomic study revealed that metformin has the potential to directly inhibit SARS-CoV-2 infection. Furthermore, retrospective clinical studies have revealed that metformin treatment reduces the mortality of T2D with COVID-19. Therefore, metformin has the potential to be repurposed to treat patients with COVID-19 at risk of developing severe illness. This review summarizes the immune pathogenesis of SARS-CoV-2 and addresses the effects of metformin on inhibiting cytokine storms and preventing SARS-CoV-2 infection, as well as its side effects.
Keywords: SARS-CoV-2; antiviral activity; coronavirus disease 2019; cytokine storm; metformin.
. 2020 Aug 18;11:2056.
doi: 10.3389/fimmu.2020.02056. eCollection 2020.
Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury
Xianyang Chen[SUP] 1 [/SUP], Huifang Guo[SUP] 1 [/SUP], Li Qiu[SUP] 2 [/SUP], Chengdong Zhang[SUP] 1 [/SUP], Qiang Deng[SUP] 3 [/SUP], Qibin Leng[SUP] 1 [/SUP]
Affiliations
- PMID: 32973814
- PMCID: PMC7461864
- DOI: 10.3389/fimmu.2020.02056
Abstract
The pandemic of coronavirus disease 2019 (COVID-19), a disease which causes severe lung injury and multiple organ damage, presents an urgent need for new drugs. The case severity and fatality of COVID-19 are associated with excessive inflammation, namely, a cytokine storm. Metformin, a widely used drug to treat type 2 diabetes (T2D) mellitus and metabolic syndrome, has immunomodulatory activity that reduces the production of proinflammatory cytokines using macrophages and causes the formation of neutrophil extracellular traps (NETs). Metformin also inhibits the cytokine production of pathogenic Th1 and Th17 cells. Importantly, treatment with metformin alleviates various lung injuries in preclinical animal models. In addition, a recent proteomic study revealed that metformin has the potential to directly inhibit SARS-CoV-2 infection. Furthermore, retrospective clinical studies have revealed that metformin treatment reduces the mortality of T2D with COVID-19. Therefore, metformin has the potential to be repurposed to treat patients with COVID-19 at risk of developing severe illness. This review summarizes the immune pathogenesis of SARS-CoV-2 and addresses the effects of metformin on inhibiting cytokine storms and preventing SARS-CoV-2 infection, as well as its side effects.
Keywords: SARS-CoV-2; antiviral activity; coronavirus disease 2019; cytokine storm; metformin.